Tacrolimus Elimination in Four Patients With aCYP3A5*3/*3 CYP3A4*22/*22Genotype Combination-Reference-Cited by-同舟云学术

Tacrolimus Elimination in Four Patients With aCYP3A5*3/*3 CYP3A4*22/*22Genotype Combination

Published:2018-06-27 Issue:7 Volume:38 Page:e46-e52
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Scheibner Aileen¹^ORCID,Remmel Rory²,Schladt David³,Oetting William S.⁴,Guan Weihua⁵,Wu Baolin⁵,Dorr Casey⁶,Israni Ajay³⁶⁷,Jacobson Pamala A.⁸

Affiliation:

1. University of Minnesota College of Pharmacy; Minneapolis Minnesota

2. Department of Medicinal Chemistry; University of Minnesota College of Pharmacy; Minneapolis Minnesota

3. Minneapolis Medical Research Foundation; Minneapolis Minnesota

4. Department of Experimental and Clinical Pharmacology; University of Minnesota; Minneapolis Minnesota

5. Division of Biostatistics; University of Minnesota; Minneapolis Minnesota

6. Division of Nephrology; Department of Medicine; Hennepin Country Medical Center; Minneapolis Minnesota

7. Epidemiology and Community Health; University of Minnesota School of Public Health; Minneapolis Minnesota

8. Department of Experimental and Clinical Pharmacology; University of Minnesota College of Pharmacy; Minneapolis Minnesota

Publisher

Wiley

Subject

Pharmacology (medical)

Reference27 articles.

1. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects;Möller;Drug Metab Dispos,1999

2. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients;de Jonge;Clin Pharmacol Ther,2012

3. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation;Staatz;Clin Pharmacokinet,2004

4. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone;Iwasaki;Drug Metab Dispos,1993

5. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro;Dai;Drug Metab Dispos,2006

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients;Pharmacogenomics;2024-01

2. Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis;Frontiers in Pharmacology;2023-07-26

3. CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study;Frontiers in Pharmacology;2023-07-04

4. Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation;Journal of Clinical Medicine;2023-07-03

5. The Design and Implementation of a Novel Pharmacogenomic Assay to Genotype the CYP3A53 (rs776746) and CYP3A51E (rs4646453) Genetic Variants;2023-04-10